Savior LLC’s Pacira BioSciences PCRX Stock Holding History

Savior LLC’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-48	Closed	-$2K	–	848
2020 Q1	$2K	Hold	48	–	–	﹤0.01%	644
2019 Q4	$2K	Buy	+48	New	+$2.04K	﹤0.01%	766

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Savior LLC's PCRX Position: Q2 2020 in Review

Savior LLC sold out of Pacira BioSciences (PCRX) in Q2 2020, closing a stake of 48 shares — an estimated $2K sold.

Savior LLC first reported a position in PCRX in Q4 2019 and held it in 2 quarters. The position peaked at $2K in Q1 2020. 248 funds tracked by Wall St. Rank hold PCRX as of Q2 2020.

Savior LLC reported no remaining Pacira BioSciences position as of Q2 2020 after selling out during the quarter.
Savior LLC sold 48 Pacira BioSciences shares in Q2 2020, an estimated $2K.
Savior LLC first reported a position in Pacira BioSciences in Q4 2019 and held it in 2 quarters.
Savior LLC's Pacira BioSciences position peaked at $2K in Q1 2020.
248 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2020.

Based on Savior LLC's 13F filing for Q2 2020, filed 28 Jul 2020.